One of science's great puzzles is being solved by artificial intelligence and the answers shared freely on the internet. How can life sciences companies make the most of DeepMind's discoveries while protecting their own?
The U.S. Supreme Court heard oral arguments Monday on the constitutionality of the Patent Trial and Appeal Board, an essential piece of the United States patent litigation puzzle and favored tool of generic and biosimilar patent challengers since its formation in 2012.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Clinical trials are a necessary part of the creation and marketing of new drugs, but the way we incentivize them contributes to our current system of exorbitant pricing.
A patent lawyer takes a closer look at the guidance on how to meet patent-eligibility standards using conclusions from recent court cases, including those denied by the Supreme Court.
American Well has already fired back. "This is Borders versus Amazon for healthcare," said Chairman and CEO Dr. Ido Schoenberg.
This will be a year in which generic drugmakers will have plenty of fodder - more than two dozen major drugs are going off-patent in 2016.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The patent protection landscape’s been turned on its head in the past couple years, ever since the Leahy-Smith America Invents Act went into effect. A discussion at trade group Biocom’s DeviceFest in San Diego this week addressed some of these changes and subtleties as they apply to medical device companies: “Gone are the days of storing the notes of […]